Page last updated: 2024-11-06

pipequaline

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Pipequaline is a synthetic anticholinergic drug with a quaternary ammonium structure. Its chemical name is 1,1'-dimethylpiperidinium bromide. It is used as a muscle relaxant and antispasmodic. It is believed to work by blocking the action of acetylcholine at the neuromuscular junction. This results in a decrease in muscle contraction. Pipequaline is studied for its potential therapeutic effects in various conditions, including Parkinson's disease, cerebral palsy, and multiple sclerosis. While some research suggests possible benefits, further investigation is needed to determine its efficacy and safety.'
```

pipequaline: anticonflict & anticonvulsant quinoline derivative; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID71219
CHEMBL ID2105206
SCHEMBL ID2110227
MeSH IDM0095477

Synonyms (38)

Synonym
pipequaline
pk-8165
pipequalina [spanish]
quinoline, 2-phenyl-4-(2-(4-piperidinyl)ethyl)-
pipequaline [inn]
pipequalinum [latin]
2-phenyl-4-(2-(4-piperidyl)ethyl)quinoline
2-phenyl-4-(2-piperidin-4-ylethyl)quinoline
2-phenyl-4-[2-(piperidin-4-yl)ethyl]quinoline
CHEMBL2105206
pipequalinum
unii-j3s205v4i2
j3s205v4i2 ,
pipequalina
77472-98-1
pipequaline [mart.]
2-phenyl-4-(2-(4-piperidyl)-ethyl)quinoline
2-phenyl-4-[2-(4-piperidinyl)ethyl]quinoline
DTXSID20228183
2-phenyl-4-[2-(4-piperidyl)-ethyl]quinoline
2-phenyl-4-[2-(4-piperidyl)-ethyl]-quinoline
AMEWZCMTSIONOX-UHFFFAOYSA-N
2-phenyl-4-[2-(4-piperidyl)ethyl] quinoline
SCHEMBL2110227
2-phenyl-4-(2-(piperidin-4-yl)ethyl)quinoline
AKOS028110703
EX-A1218
quinoline, 2-phenyl-4-[2-(4-piperidinyl)ethyl]-
AS-66087
HY-100140
CS-6386
BCP19330
DB13991
mfcd00866983
Q7197283
AMY10840
CDA47298
AC-36836

Research Excerpts

Overview

Pipequaline (PK 8165) is a putative mixed agonist/antagonist at benzodiazepine receptors.

ExcerptReferenceRelevance
"Pipequaline (PK 8165) is a putative mixed agonist/antagonist at benzodiazepine receptors. "( The effects on memory of pipequaline, alone or in combination with diazepam.
Curran, HV; Eves, FF; Lader, MH; Shine, P, 1988
)
2.02

Compound-Compound Interactions

ExcerptReferenceRelevance
"The effects of several compounds believed to act at the GABA-benzodiazepine receptor complex and which have anticonvulsant or proconvulsant properties when administered in combination with picrotoxin and pentetrazol (leptazol, pentylenetetrazole) were investigated in combination with the convulsant benzodiazepine Ro 5-4864."( Pro- and anti-convulsant drug effects in combination with the convulsant benzodiazepine Ro 5-4864.
File, SE; Pellow, S, 1985
)
0.27
" 3 When the phenylquinolines were combined with chlordiazepoxide the degree of sedation was equal to that seen with either drug given alone, whichever produced the greater sedation; the sedative effects of the two drugs were never additive."( Sedative effects of PK 9084 and PK 8165, alone and in combination with chlordiazepoxide.
File, SE, 1983
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
PPM1D proteinHomo sapiens (human)Potency29.41070.00529.466132.9993AID1347411
Interferon betaHomo sapiens (human)Potency29.41070.00339.158239.8107AID1347411
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (30)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (33)

TimeframeStudies, This Drug (%)All Drugs %
pre-199030 (90.91)18.7374
1990's2 (6.06)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (3.03)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 18.10

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index18.10 (24.57)
Research Supply Index3.64 (2.92)
Research Growth Index4.11 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (18.10)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (12.12%)5.53%
Reviews1 (3.03%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other28 (84.85%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]